Dallas, Texas 02/21/2014 (FINANCIALSTRENDS) – Acura Pharmaceuticals, Inc.(NASDAQ:ACUR), the Palatine, IL has begun to attract analyst attention in the recent weeks. The company which offers specialized pharma products which treats abuse of medical products has received a well-deserved research note by Zacks.
Acura Pharmaceuticals, Inc.(NASDAQ:ACUR) was found to have made quite a jump on the stock markets, revealing an overall jump of 5%. The rally was seen to be higher than normal. This was attributed to the solid volume changes this stock brought in. The company also noted that the number of shares it was handling were higher than the normal session. It also noted that the trend had reversed from recent reverse movements. The stock was found to have traded high, reaching $1.59 or $1.81 in the past one-month.
Acura Pharmaceuticals, Inc.(NASDAQ:ACUR) has in the past 30 days also found that the company has been part of a higher revisions from the previous returns. In comparison, stocks such as AlexionPharmceuticalInc, GentiumS.p.A as well as Cambrex Corporation were found to have moved much higher on the stock market. It was also found that the stock was trading at higher than expectations for these stocks.
Acura Pharmaceuticals, Inc.(NASDAQ:ACUR) has a strong product in Aversion. This product is a mixture of ingredients which are inactive and are found to have incorporated the pharmaceutical tablets as well as the capsules which are designed to hold better means and methods to prevent tampering of products which are related to the abuse of products. Another is the Impede Technology combination which has inactive ingredients which work on the lines of pseudoephedrine which is from tables and are known to disrupt the conversion directly. Here it is the prevention of conversion from pseudoephedrine into mehtampehtamine.
Acura Pharmaceuticals, Inc.(NASDAQ:ACUR) is also in the process of building products such as the seven opioid products which use Aversion.